Evidence map›Paper›PMID 37891179›Full record

ArticleScientific reports2023

An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome).

Kari Pollock, Sabrina Noritake, Denise M Imai, Gabrielle Pastenkos, Marykate Olson, Whitney Cary, Sheng Yang, Fernando A Fierro, Jeannine White, Justin Graham and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kari PollockStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA. kmpollock@ucdavis.edu.
Sabrina NoritakeStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Denise M ImaiComparative Pathology Laboratory, University of California Davis, School of Veterinary Medicine, Davis, CA, USA.
Gabrielle PastenkosComparative Pathology Laboratory, University of California Davis, School of Veterinary Medicine, Davis, CA, USA.
Marykate OlsonStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Whitney CaryStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Sheng YangStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Fernando A FierroStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Jeannine WhiteStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Justin GrahamStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Heather DahlenburgStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
Karl JoheReMotor Therapeutics, Inc., San Diego, CA, USA.
Jan A NoltaStem Cell Program and Institute for Regenerative Cures, University of California Davis Health System, Sacramento, CA, USA.
University of California, Davis · USCalifornia Institute for Regenerative Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucopolysaccharidosis III (MPSIII, Sanfilippo syndrome) is a devastating lysosomal storage disease that primarily affects the central nervous system. MPSIIIA is caused by loss-of-function mutations in the gene coding for sulfamidase (N-sulfoglucosamine sulfohydrolase/SGSH) resulting in SGSH enzyme deficiency, a buildup of heparin sulfate and subsequent neurodegeneration. There is currently no cure or disease modifying treatment for MPSIIIA. A mouse model for MPSIIIA was characterized in 1999 and later backcrossed onto the C57BL/6 background. In the present study, a novel immune deficient MPSIIIA mouse model (MPSIIIA-TKO) was created by backcrossing the immune competent, C57BL/6 MPSIIIA mouse to an immune deficient mouse model lacking Rag2, CD47 and Il2rg genes. The resulting mouse model has undetectable SGSH activity, exhibits histological changes consistent with MPSIIIA and lacks T cells, B cells and NK cells. This new mouse model has the potential to be extremely useful in testing human cellular therapies in an animal model as it retains the MPSIIIA disease phenotype while tolerating xenotransplantation.

Indexed as

Mucopolysaccharidosis IIIAnimalsDisease Models, AnimalHumansHydrolasesMiceMice, Inbred C57BLPhenotypeHydrolases

Identifiers

PMID37891179
PMCPMC10611714
OpenAlexW4387972247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.